Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.72 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.67 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299999 | 1.00 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL10932073 | 0.85 | CYP19A1 (0.73) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL11633201 | 0.84 | CYP19A1 (0.73) | CYP19A1HMOX1 | |
| SCHEMBL11983140 | 0.84 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL4313095 | 0.84 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL11266884 | 0.84 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL10197408 | 0.84 | HMOX1 (0.91) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL10816487 | 0.84 | HMOX1 (0.91) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL6173273 | 0.83 | CYP19A1 (0.71) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL6299346 | 0.83 | CYP19A1 (0.71) | CYP19A1HMOX1CYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894461-B | Novel coumarin-containing azole derivative, and preparation method and application thereof | 沈阳药科大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-115028585-B | Arylalkylazole derivative and application thereof | 聊城大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-115894461-A | Novel coumarin azole-containing derivative and preparation method and application thereof | 沈阳药科大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-115028585-A | Arylalkanazole derivatives and use thereof | 聊城大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-109320458-B | Diaryl imidazole-containing compound, preparation method and medical application thereof | 中国药科大学 | 2022-05-31 | — | — | CN | disclosed |
| CN-112694472-A | BuChE-IDO1 inhibitor, preparation method and application thereof | 西南大学 | 2021-04-23 | — | — | CN | disclosed |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| EP-0276583-A1 | Imidazole derivatives, processes for their preparation and their fungicidal properties | Instituto de Investigacion Y Desarrollo Quimico Biologico S.A. (ES) | 1988-08-03 | — | — | EP | disclosed |
| US-4349556-A | Pesticidally active 1-acyloxy-1-phenyl-2-azolyl-ethanes | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | CYP19A1 836/4885HMOX1 4023/4885CYP51A1 75/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | CYP19A1 806/4885HMOX1 3930/4885CYP51A1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.